End Gas Station Heroin Act
- Sponsor
- Sen. Moreno, Bernie [R-OH]
- Committees
- Judiciary Committee (primary)
- Last action
- Aug 8, 2026
Bottom line
The bill aims to combat the proliferation of highly potent synthetic opioids, including concentrated kratom derivatives, by expanding federal scheduling and enforcement powers against manufacturers and distributors, while attempting to safeguard traditional kratom.
What it actually does
This bill amends the Controlled Substances Act (CSA) to specifically classify synthetic 7-hydroxymitragynine and mitragynine pseudoindoxyl as Schedule I controlled substances, with an exemption for naturally occurring forms in kratom products below specified concentration thresholds. It also establishes a new enforcement mechanism to treat "covered emerging synthetic opioids" as Schedule I substances for manufacturing and distribution offenses, without requiring individual scheduling actions for each new substance, while explicitly exempting simple possession.
Proponents argue
Proponents argue this bill is a crucial step in addressing the public health crisis posed by novel synthetic opioids, often marketed deceptively. They contend it provides law enforcement with necessary tools to quickly target dangerous substances, like "gas station heroin," that are chemically modified to evade existing drug schedules, thereby saving lives and preventing addiction without unduly criminalizing low-potency natural products.
Opponents contend
Opponents, particularly those advocating for kratom access, might argue that even with exemptions, the bill's broad language could inadvertently harm the legitimate kratom industry and consumers. They may also express concerns about the potential for overreach in defining "covered emerging synthetic opioids" and the implications for research or future substances, suggesting that a more nuanced, science-driven approach to scheduling is preferable to broad, anticipatory prohibitions.
The bill is short and relatively clear, allowing an informed reader to grasp its core provisions within the typical time available for legislative review.
Section 2
Schedule I Classification for Specific Kratom Alkaloids
This provision adds synthetic 7-hydroxymitragynine and mitragynine pseudoindoxyl, which are potent compounds sometimes derived from the kratom plant, to Schedule I of the Controlled Substances Act. This means their manufacture, distribution, and possession (with intent to distribute) would be illegal, similar to heroin or LSD. However, it includes specific exemptions for these compounds when they occur naturally in kratom or kratom products, provided their concentrations do not exceed very low thresholds (e.g., 1 milligram per gram of product or 1 part per 100 parts mitragynine).
Supporters argue
Supporters argue that these specific compounds, especially in synthetic or concentrated forms, are highly potent and contribute to opioid-like addiction and overdose risks, necessitating their Schedule I classification to protect public health. The carefully crafted exemptions ensure that traditional kratom products, which are generally less potent, remain accessible.
Critics contend
Some kratom advocates might argue that even with exemptions, scheduling any kratom-related compound could set a dangerous precedent, potentially leading to broader restrictions on kratom in the future. They might also contend that the thresholds are arbitrary or difficult for consumers and small businesses to verify, creating uncertainty.
Tradeoffs
The provision balances the public health concern over highly potent synthetic opioids with the desire to avoid criminalizing naturally occurring, lower-potency botanical products. The tension lies in defining the precise line between a dangerous synthetic and a natural product.
Section 3
Broadened Enforcement for "Covered Emerging Synthetic Opioids"
This section creates a new, broader enforcement tool for the Attorney General to target "covered emerging synthetic opioids." These are defined as commercially distributed, non-FDA approved, synthetic or semi-synthetic substances that act as potent opioid receptor agonists (more potent than morphine) and are intended for human consumption. For these substances, manufacturing, distribution, and possession with intent to distribute are treated as Schedule I offenses, even if the substance hasn't been individually scheduled by the DEA. Crucially, it explicitly states that simple possession or personal use of these substances will not be subject to criminal or civil enforcement under this section.
Section 3(i)(4) defines "semisynthesis" as "the chemical modification or conversion of a naturally occurring substance into a chemically distinct substance." This definition, combined with Section 3(g)(3), which excludes naturally occurring constituents unless they have been "intentionally, isolated, enriched, concentrated, chemically converted, or added to a product for human consumption," means that even if a substance starts as natural, if it undergoes chemical modification to become a "chemically distinct substance" or is concentrated, it can lose its natural exemption and be treated as a "covered emerging synthetic opioid."
Section 3(i)(4) and Section 3(g)(3)
Why it matters:This is standard legislative practice for defining terms, but its interplay with the exclusions is critical for understanding the scope of the bill's reach.
Case for: Supporters would argue this is necessary to prevent manufacturers from taking a naturally occurring, less potent substance, chemically modifying it slightly, and then claiming it's "natural" to evade scheduling, even if the modified substance is highly potent and dangerous. It closes a potential loophole.
Case against: Critics might argue that this broad definition could inadvertently capture substances that are only minimally modified or concentrated for legitimate purposes, creating a chilling effect on innovation or the development of beneficial natural product derivatives, even if they are not intended to be "opioids."
Estimated impact: Potentially significant for the development and commercialization of any substance derived from natural sources that undergoes chemical modification or concentration, particularly if it has any opioid receptor activity.
A "covered emerging synthetic opioid" must "demonstrate greater functional potency than morphine at the human mu-opioid receptor in a validated assay identified by regulation, or demonstrate greater analgesic or respiratory-depressant potency than morphine based on other scientifically reliable evidence." This sets a scientific threshold for what constitutes a "covered emerging synthetic opioid."
Section 3(c)(2)
Why it matters:This is standard for technical definitions in drug scheduling legislation, ensuring a scientific basis for enforcement.
Case for: Proponents would argue that this scientific threshold is crucial for ensuring that only genuinely dangerous and potent opioid-like substances are targeted, preventing overreach and focusing enforcement on substances with significant public health risks. It provides an objective measure.
Case against: Critics might argue that "validated assay identified by regulation" and "scientifically reliable evidence" could still leave room for interpretation or rapid changes in scientific consensus, potentially leading to inconsistent application or challenges in court. The process for identifying and validating these assays is not specified in the bill.
Estimated impact: This provision dictates which substances fall under the new enforcement regime, making it foundational to the bill's scope. Its interpretation will determine the practical reach of the law.